MENU TEGSEDI® (inotersen) • To view full prescribing information for TEGSEDI® (inotersen), including BOXED WARNING information, please click here • To learn more please visit www.tegsedi.com • To view full EU prescribing information for TEGSEDI, please visit www.ema.europa.eu/en • For more information please visit www.akceatx.ca Careers | Privacy Policy | Terms of Use | Contact | Compliance Governance Documents Akcea Therapeutics 22 Boston Wharf Road, 9th Floor, Boston MA 02210 (617) 207-0202 info@akceatx.com © 2021, all rights reserved Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below. Go to ionispharma.com

MENU hATTR Compass Genetic Testing hATTR Compass Genetic Testing and Counseling Program Akcea Therapeutics and Ambry Genetics are partnering to offer anonymous, no-cost genetic testing and confidential genetic counseling to patients suspected of having or clinically diagnosed with hATTR amyloidosis through the hATTR Compass program. hATTR Compass is Designed to: Help accelerate or confirm the diagnosis of hATTR amyloidosis Provide support and resources to patients, caregivers and healthcare professionals throughout the genetic testing process Empower patients and their healthcare professionals to make the most informed decisions about their health care The hATTR Compass Program is available for patients in the U.S. and Canada who are 18 years and older and have a family history of hATTR amyloidosis. If there is no family history, the patient must have at least two clinical symptoms or manifestations related to hATTR amyloidosis. For more information and resources, please visit – www.hATTRCompass.com. Careers | Privacy Policy | Terms of Use | Contact | Compliance Governance Documents Akcea Therapeutics 22 Boston Wharf Road, 9th Floor, Boston MA 02210 (617) 207-0202 info@akceatx.com © 2021, all rights reserved Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below. Go to ionispharma.com